Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment

Proteomics

Volumn 10, Issue 1, 2010, Pages 90-98

  Liang, Tingting ^a   Wang, Na ^b   Li, Wei ^a   Li, Ailing ^b   Wang, Jie ^b   Cui, Jiuwei ^a   Liu, Nian ^a   Li, Yan ^b   Li, Ng ^a   Yang, Guozi ^a   Du, Zhonghua ^a   Li, Dan ^a   He, Kun ^b   Wang, Guanjun ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

Author keywords

Acute leukemia (AL); Biomedicine complement; Minimal residual disease (MRD); MS

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3F DESARG; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERUM; SUPPORT VECTOR MACHINE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ARGININE; COMPLEMENT C3B; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM, RESIDUAL; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 73549124550     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200900513     Document Type: Article

References (29)

1. Haferlach, T., Bacher, U., Kern, W., Schnittger, S., Haferlach, C., Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann. Hematol. 2007, 86, 311-327.
2. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G. et al., Proposals for the classification of the acute leukemias (FAB cooperative group). Br. J. Haematol. 1976, 33, 451-458.
3. Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D. et al., The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114, 937-951.
4. Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W. et al., Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003, 17, 2318-2357.
5. Kern, W., Voskova, D., Schoch, C., Hiddemann, W. et al., Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004, 104, 3078-3085.
6. Cui, J. W., Wang, J., He, K., Jin, B. F. et al., Proteomic analysis of human acute leukemia cells: insight into their classification. Clin. Cancer Res. 2004, 10, 6887-6896.
7. Cui, J. W., Li, W. H., Wang, J., Li, A. L. et al., Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol. Cell. Proteomics 2005, 4, 1718-1724.
8. Cristea, I. M., Gaskell, S. J., Whetton, A. D, Proteomics techniques and their application to hematology. Blood 2004, 103, 3624-3634.
9. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumorspecific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
10. Cheng, A. J., Chen, L. C., Chien, K. Y., Chen, Y. J. et al., Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 2005, 51, 2236-2244.
11. Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J. et al., Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 2006, 5, 1840-1852.
12. Hu, S., Loo, J. A., Wong, D. T., Human body fluid proteome analysis. Proteomics 2006, 6, 6326-6353.
13. Villanueva, J., Lawlor, K., Toledo-Crow, R., Tempst, P., Automated serum peptide profiling. Nat. Protoc. 2006, 1, 880-891.
14. Estey, E., Döhner, H., Acute myeloid leukaemia. Lancet 2006, 368, 1894-1907.
15. Santamaría, C., Chillón, M. C., Fernández, C., Martín-Jiménez, P. et al., Using quantification of the PML-RARα transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 2007, 92, 315-322.
16. Wang, N., Dong, F. T., Zhang, X. M., Li, A. L. et al., Hydrothermal synthesis of metal-chelated magnetic nanobeads for exclusive use of peptides extraction by mass spectrum. Acta Chimica. Sinica. 2007, 65, 344-348.
17. Cao, Y., Wang, N., Ying, X. M., Li, A. L. et al., BioSunMS: A plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry. BMC. Med. Inform. Decis. Mak. 2009, 9, 13.
18. Stanley, Ng. K. L., Mishra, S. K., De novo SVM classification of precursor microRNAs from genomic pseudo hairpins using global and intrinsic folding measures. Bioinformatics 2007, 23, 1321-1330.
19. van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T. et al., Detection of minimal residual diseases in hematologic malignances by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17, 1013-1034.
20. Maurillo, L., Buccisano, F., Spagnoli, A., Poeta, G. D. et al., Monitoring of residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 2007, 92, 605-611.
21. Hortin, G. L., The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52, 1223-1237.
22. Janssen Bert, J. C., Huizinga, E. G., Raaijmakers Hans, C. A., Roos, A. et al., Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437, 505-511.
23. Ganu,V. S., Muller-Eberhard, H. J., Hugli, T. E., Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized. Mol. Immunol. 1989, 26, 939-948.
24. Yang, X., Toshihiro, M., Kosuke, M., Kota, S. et al., Comprehensive investigation of disease-specific short peptidesin sera from patients with systemic sclerosis Complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Arth. Rheum. 2007, 56, 2018-2030.
25. Carroll, M. C., The complement system in regulation of adaptive immunity. Nat. Immunol. 2004, 5, 981-986.
26. Ziller, F., Macor, P., Bulla, R., Sblattero, D. et al., Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 2005, 35, 2175-2183.
27. Rozanov, D. V., Savinov, A. Y., Golubkov, V. S., Tomlinson, S., Strongin, A.Y., Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res. 2006, 66, 6258-6263.
28. Ajona, D., Castaño, Z., Garayoa, M., Zudaire, E. et al., Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 2004, 64, 6310-6318.
29. Walport, M. J., Complement-Second of two parts. N. Engl. J. Med. 2001, 344, 1140-1144.